Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| STRO | SUTRO BIOPHARMA, INC. | 2026-04-02 18:14:34 | 23.49 | -0.29 | -1.22 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STRO | 0001382101 | SUTRO BIOPHARMA, INC. | US8693672011 | 5493005U6P15VD25P851 | 452441988 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | — | 111 OYSTER POINT BLVD. | SOUTH SAN FRANCISCO | CA | 94080 | UNITED STATES | US | 650-392-8412 | 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080 | 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080 | SUTRO BIOPHARMA INC | Biotechnology | 2003 | — | 290 | http://sutrobio.com | 60,000,000 | 8,584,309 | 16,567,238 | Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. | 2026-04-02 18:07:03 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 60,000,000 | -177,800,000 | -74.7687 | 16,567,238 | -67,208,098 | -80.2242 |
| 2024 | 237,800,000 | -40,500,000 | -14.5526 | 83,775,336 | 21,333,373 | 34.1651 |
| 2023 | 278,300,000 | 27,600,000 | 11.0092 | 62,441,963 | 2,281,412 | 3.7922 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 137 |
| 2024 | 310 |
| 2023 | 302 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 102,484,000 | 62,043,000 | 153,731,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 166,417,000 | 252,043,000 | 180,425,000 |
| General And Administrative Expenses | 41,019,000 | 48,453,000 | 62,584,000 |
| Operating Expenses | 260,851,000 | 300,496,000 | 243,009,000 |
| Operating Income | -158,367,000 | -238,453,000 | -89,278,000 |
| Net Income | -191,086,000 | -227,461,000 | -106,793,000 |
| Earnings Per Share Basic | -22.49 | -2.96 | -1.78 |
| Earnings Per Share Diluted | -22.49 | -2.96 | -1.78 |
| Weighted Average Shares Outstanding Basic | 8,497,798 | 76,829,198 | 60,163,542 |
| Weighted Average Shares Outstanding Diluted | 8,497,798 | 76,829,198 | 60,163,542 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 58,130,000 | 190,304,000 | 69,268,000 |
| Marketable Securities Current | 83,298,000 | 126,591,000 | 264,413,000 |
| Accounts Receivable | 3,977,000 | 8,616,000 | 36,078,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 150,926,000 | 343,310,000 | 421,542,000 |
| Marketable Securities Non Current | 0 | 0 | 0 |
| Property Plant And Equipment | 10,648,000 | 18,190,000 | 21,940,000 |
| Other Assets Non Current | 495,000 | 7,172,000 | 3,567,000 |
| Total Assets Non Current | 22,904,000 | 43,897,000 | 49,194,000 |
| Total Assets | 173,830,000 | 387,207,000 | 470,736,000 |
| Accounts Payable | 7,565,000 | 10,475,000 | 9,440,000 |
| Deferred Revenue | 10,562,000 | 69,783,000 | 20,666,000 |
| Short Term Debt | — | — | 4,061,000 |
| Other Liabilities Current | 2,913,000 | 4,009,000 | 3,897,000 |
| Total Liabilities Current | 75,133,000 | 131,893,000 | 93,746,000 |
| Long Term Debt | — | — | 4,061,000 |
| Other Liabilities Non Current | 1,694,000 | 1,694,000 | 1,694,000 |
| Total Liabilities Non Current | 231,149,000 | 210,713,000 | 227,341,000 |
| Total Liabilities | 306,282,000 | 342,606,000 | 321,087,000 |
| Common Stock | 9,000 | 83,000 | 61,000 |
| Retained Earnings | -977,955,000 | -786,869,000 | -559,408,000 |
| Accumulated Other Comprehensive Income | 19,000 | 39,000 | 21,000 |
| Total Shareholders Equity | -132,452,000 | 44,601,000 | 149,649,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 7,324,000 | 7,218,000 | 6,816,000 |
| Share Based Compensation Expense | 14,008,000 | 24,687,000 | 24,908,000 |
| Other Non Cash Income Expense | -571,000 | -766,000 | -622,000 |
| Change In Accounts Receivable | -4,639,000 | -27,462,000 | 28,956,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,468,000 | 706,000 | 4,812,000 |
| Change In Other Liabilities | 3,552,000 | -7,354,000 | 25,300,000 |
| Cash From Operating Activities | -177,231,000 | -191,540,000 | -111,616,000 |
| Purchases Of Marketable Securities | 264,950,000 | 461,521,000 | 460,301,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 45,013,000 | 218,508,000 | -3,924,000 |
| Tax Withholding For Share Based Compensation | 332,000 | 509,000 | 490,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 25,000,000 | 11,971,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 44,000 | 94,054,000 | 137,554,000 |
| Change In Cash | -132,174,000 | 121,022,000 | 22,014,000 |
| Cash At End Of Period | 58,130,000 | 190,304,000 | 69,268,000 |
| Income Taxes Paid | 75,000 | 17,520,000 | 379,000 |
| Interest Paid | 0 | 310,000 | 1,126,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -22.49 | -2.96 | -1.78 |
| Price To Earnings Ratio | -0.5145 | -6.2162 | -24.1011 |
| Earnings Growth Rate | 659.7973 | 66.2921 | -24.2553 |
| Price Earnings To Growth Ratio | -0.0008 | -0.0938 | 0.9936 |
| Book Value Per Share | -15.5866 | 0.5805 | 2.4874 |
| Price To Book Ratio | -0.7423 | 31.6956 | 17.2471 |
| Ebitda | -183,687,000 | -202,723,000 | -98,298,000 |
| Enterprise Value | — | — | 2,519,869,951.8 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.0543 |
| Capital Expenditures | -218,000 | 3,468,000 | 4,135,000 |
| Free Cash Flow | -177,013,000 | -195,008,000 | -115,751,000 |
| Return On Equity | 1.4427 | -5.0999 | -0.7136 |
| One Year Beta | 1.411 | 2.1022 | 1.2094 |
| Three Year Beta | 1.5014 | 1.351 | 1.1995 |
| Five Year Beta | 1.3439 | 1.477 | 1.4624 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Chung Jane | Director, Chief Executive Officer | 2026-03-04 | 788 | A | 21,567 |
| Chung Jane | Director, Chief Executive Officer | 2026-03-04 | 282 | D | 21,285 |
| Chung Jane | Director, Chief Executive Officer | 2026-03-04 | 788 | D | 0 |
| Pauling David | Chief Admin. Ofcr. & GC | 2026-03-04 | 675 | A | 10,025 |
| Pauling David | Chief Admin. Ofcr. & GC | 2026-03-04 | 277 | D | 9,748 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 181,290 | 15,669 | 11.57 |
| Invesco Ltd. | 2025-12-31 | 196,343 | 16,970 | 11.57 |
| ADAR1 Capital Management, LLC | 2025-12-31 | 776,081 | 67,077 | 11.57 |
| State of Tennessee, Department of Treasury | 2025-12-31 | 110,630 | 7,400 | 14.95 |
| AQR CAPITAL MANAGEMENT LLC | 2025-12-31 | 208,654 | 18,034 | 11.57 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 16,901 | 252,669.95 | 0.0094 |
| Advisors' Inner Circle Fund III | 2026-01-31 | I Shares | KCXIX | 41 | 614.45 | 0.0002 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VITPX | 2,385 | 27,594.45 | 0.0001 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Shares | VITNX | 2,385 | 27,594.45 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Select Shares | VSTSX | 235,624 | 2,726,169.68 | 0.0001 |